BOCA RATON, Fla.-- (BUSINESS WIRE)--March 19, 2026-- ...

Key Takeaways. LGM Pharma’s Texas expansion targets commercial suppository manufacturing and broader semi-solid/liquid ...

The Central Drugs Standard Control Organisation (CDSCO) has directed all State and Union Territory Drugs Controllers to take immediate action against the manufacturing and marketing ...

Industry experts discuss the benefits of utilizing contract development and contract research organizations in drug discovery and development. Drug discovery can involve extensive research to identify ...

CDSCO asks SLAs to cancel product permission to sodium hyaluronate eye drops 0.3% w/v: Gireesh Babu, New Delhi Friday, March 20, 2026, 08:00 Hrs [IST] The Central Drugs Standard C ...

Pharmaceutical major Dr. Reddy''s Laboratories Ltd on Saturday announced the launch of its injectable semaglutide under the brand name Obeda, a type 1 diabetes drug in India.

Generic drugmakers in India launch affordable Semaglutide versions, targeting a $1 billion diabetes and weight loss market.

QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...

Over the next 5 years, Gland Pharma plans to invest approximately Rs 20 bn in capex, primarily towards BFS and ophthalmic ...

Dr Reddy's Laboratories has announced the launch of its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to GLP-1 receptor agonist-based therapy for the ...